Journal Home
Search for

Volume 35, Issue 5, Pages 497-499 (May 2010)


View previous. 16 of 26 View next.

Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin

Matthew E. FalagasabcCorresponding Author Informationemail address, Sofia Marakid, Drosos E. Karageorgopoulosa, Antonia C. Kastorisa, Anastasios Kapaskelisac, George Samonise

Received 14 December 2009; accepted 5 January 2010. published online 15 March 2010.

Abstract 

We aimed to evaluate the antimicrobial activity of fosfomycin against Gram-positive non-urinary isolates collected at the microbiological laboratory of the University Hospital of Heraklion, Crete, Greece, in 2008. Susceptibility testing was performed by the disk diffusion method for a total of 1846 isolates; 1275 isolates (69.1%) were susceptible to fosfomycin. Specifically, 416/419 Staphylococcus aureus (99.3%) [including 129/130 meticillin-resistant S. aureus (MRSA) isolates] and 745/961 coagulase-negative staphylococci (77.5%) were susceptible to fosfomycin. Among 42 Streptococcus pneumoniae, 64 Streptococcus pyogenes and 93 other streptococcal isolates, 61.9%, 40.6% and 48.4%, respectively, were susceptible to fosfomycin. Fosfomycin was inactive against the 166 enterococcal isolates tested. This old antibiotic may deserve consideration for further studies and use in clinical practice, especially for S. aureus (including MRSA) infections.

a Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece

b Department of Medicine, Tufts University School of Medicine, Boston, MA, USA

c Department of Medicine, Henry Dunant Hospital, Athens, Greece

d Department of Clinical Bacteriology, University Hospital of Heraklion, Heraklion, Crete, Greece

e Department of Medicine, University Hospital of Heraklion, Heraklion, Crete, Greece

Corresponding Author InformationCorresponding author. Tel.: +30 694 611 0000; fax: +30 210 683 9605.

PII: S0924-8579(10)00053-1

doi:10.1016/j.ijantimicag.2010.01.010


View previous. 16 of 26 View next.